A maker of
immunological and other pharmaceuticals, Biofarma built the production center from the
ground up in 2.5 years, company chairman Oleksandr Makovsky said.
The project stems
from an infusion of cash that the Kyiv-based company received in exchange for
stakes in October 2012 from Holland’s development bank FMO and Ukraine-based
private equity fund manager Horizon Capital.